Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 120 mg/6 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 108–109
HOS-214784 · Präparat HOS-155350
108 MedDRA system Very common adverse Common adverse Uncommon adverse organ classes reactions reactions reactions (G3/4: 0.4%) Cardiac disorders Cardiac failure; Arrhythmia (no severe) Vascular disorders Hypotension Gastrointestinal Nausea (G3/4: 5%); disorders Stomatitis (G3/4: 7.8%); Diarrhoea (G3/4: 6.2%); Vomiting (G3/4: 5%); Constipation Skin and subcutaneous Alopecia; tissue disorders Nail disorders (severe: 0.4%); Skin reaction (no severe) Musculoskeletal and Myalgia connective tissue disorders General disorders and Asthenia Infusion site reaction administration site (severe: 8.1%); conditions Fluid retention (severe: 1.2%); Pain Investigations G3/4 Blood bilirubin G3/4 AST increased increased (< 2.5%); (< 1%); G3/4 Blood alkaline G3/4 ALT increased phosphatase increased (< 1%) (< 2.5%)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage 9d5644752284878c5e8d9e72416946eec7df47e32ed78eabc43735a55c13729a · Zeichen 13201–14886 im Abschnitt